1. Miceli MC, Nelson SF. The case for eteplirsen: paving the way for precision medicine. Mol Genet Metab. 2016;118(2):70–1.
2. Sarepta Therapeutics Inc. Eteplirsen briefing document (NDA 206488). 2016. http://www.fda.gov . Accessed 5 Oct 2016.
3. Sarepta Therapeutics Inc. Exondys 51(eteplirsen) injection, for intravenous use: US prescribing information. 2016. http://www.fda.gov . Accessed 6 Oct 2016.
4. Sarepta Therapeutics Inc. United States Securities And Exchange Commission filing: form 10-K for the fiscal year ended December 31, 2015. 2016. http://www.sarepta.com . Accessed 5 Oct 2016.
5. Sarepta Therapeutics Inc. Sarepta Therapeutics receives rare pediatric disease designation from FDA for eteplirsen for the potential treatment of Duchenne muscular dystrophy [media release]. 21 Aug 2015. http://www.sarepta.com .